Atorlip 20: Effective LDL Cholesterol Management

Atorlip 20

Atorlip-20 is used to treat high cholesterol.

Product dosage: 5mg
Package (num)	Per pill	Price	Buy
30	2.89 $	86.58 $ (0%)	🛒 Add to cart
60	2.59 $	173.16 $ 155.61 $ (10%)	🛒 Add to cart
90	2.50 $	259.74 $ 224.64 $ (14%)	🛒 Add to cart
120	2.43 $	346.32 $ 291.33 $ (16%)	🛒 Add to cart
180	2.39 $	519.48 $ 429.39 $ (17%)	🛒 Add to cart
270	2.35 $ Best per pill	779.22 $ 634.14 $ (19%)	🛒 Add to cart

Similar products

Atorlip 20 contains atorvastatin calcium, a potent lipid-lowering medication belonging to the statin class. It is indicated as an adjunct to diet and other non-pharmacological measures to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in adults, adolescents, and children aged 10 years and older with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. It is also used to reduce the risk of cardiovascular events in patients with multiple risk factors but without established coronary heart disease. Manufactured under strict pharmaceutical standards, Atorlip 20 ensures consistent dosing, bioavailability, and therapeutic reliability for long-term cardiovascular risk management.

Features

Active ingredient: Atorvastatin calcium 20 mg
Pharmaceutical form: Film-coated tablet
Pack sizes: 28 or 30 tablets per blister strip
Excipients: Calcium carbonate, croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, opadry white, polysorbate 80, simethicone emulsion
Storage: Below 30°C in a dry place, protected from light
Manufacturer: Complies with Good Manufacturing Practice (GMP) standards
Prescription-only medication

Benefits

Significantly reduces low-density lipoprotein (LDL) cholesterol levels, slowing the progression of atherosclerosis
Lowers the risk of myocardial infarction, stroke, and revascularization procedures in high-risk patients
Increases high-density lipoprotein (HDL) cholesterol, supporting reverse cholesterol transport
Provides anti-inflammatory effects within vascular endothelium, improving endothelial function
Offers convenient once-daily dosing, supporting long-term adherence to therapy
Suitable for a wide patient demographic, including paediatric populations (10 years and older) with familial hypercholesterolaemia

Common use

Atorlip 20 is primarily prescribed for patients diagnosed with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, where lifestyle modifications alone are insufficient. It is also indicated to reduce cardiovascular risk in adult patients with hypertension, history of stroke, type 2 diabetes, or other risk factors, even if cholesterol levels are only moderately elevated. In paediatric patients aged 10 years and older with heterozygous familial hypercholesterolaemia, it is used after failure of diet and other non-pharmacological measures.

Dosage and direction

The recommended starting dose for most patients is Atorlip 20 once daily, which may be adjusted based on lipid-level response and tolerability, up to a maximum of 80 mg daily. Dosage should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response. It can be taken with or without food, at any time of day, though consistency in timing is advised. Liver function tests must be performed before initiation and periodically thereafter. Dose adjustments are necessary in patients taking concomitant cytochrome P450 3A4 inhibitors or with predisposing factors for myopathy.

Precautions

Liver function: Check serum transaminases before starting treatment and periodically thereafter; discontinue if persistent elevations occur
Muscle effects: Patients should report unexplained muscle pain, tenderness, or weakness; monitor creatine kinase if symptoms appear
Renal impairment: Dose adjustment is not typically necessary, but caution is advised in patients with severe renal impairment
Elderly patients: No specific dose adjustment required, but increased susceptibility to side effects should be considered
Pregnancy and breastfeeding: Contraindicated; discontinue Atorlip 20 if pregnancy occurs
Alcohol: Patients should avoid excessive alcohol consumption due to increased risk of hepatotoxicity
Diabetes: May increase HbA1c and fasting serum glucose levels; monitor glucose parameters periodically

Contraindications

Hypersensitivity to atorvastatin or any excipients in the formulation
Active liver disease or unexplained persistent elevations of serum transaminases
Pregnancy, women planning pregnancy, and breastfeeding
Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors)
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption

Possible side effect

Common side effects (≥1/100 to <1/10):

Headache
Insomnia
Nausea, diarrhoea, dyspepsia
Myalgia, arthralgia
Increased liver enzymes

Uncommon side effects (≥1/1,000 to <1/100):

Constipation, flatulence
Rash, pruritus
Dizziness, paraesthesia
Fatigue, asthenia

Rare side effects (≥1/10,000 to <1/1,000):

Hepatitis, jaundice
Pancreatitis
Peripheral neuropathy
Memory loss, confusion

Very rare side effects (<1/10,000):

Rhabdomyolysis with renal dysfunction
Tendon rupture
Lupus-like syndrome
Gynecomastia

Drug interaction

Strong CYP3A4 inhibitors: Avoid concomitant use (e.g., clarithromycin, itraconazole, HIV protease inhibitors)
Gemfibrozil and other fibrates: Increased risk of myopathy; use with caution and at lowest necessary doses
Niacin: May increase risk of myopathy; monitor closely
Cyclosporine, telaprevir: Significantly increase atorvastatin exposure; avoid or use lowest dose
Oral contraceptives: May increase hormone levels; monitor for adverse effects
Warfarin: May enhance anticoagulant effect; monitor INR regularly
Digoxin: May increase digoxin concentration; monitor levels
Colchicine: Increased risk of myopathy, especially in elderly or renally impaired patients

Missed dose

If a dose is missed, take it as soon as remembered on the same day. If it is nearly time for the next dose, skip the missed dose and resume the usual dosing schedule. Do not take a double dose to make up for a missed one. Consistent daily dosing is important for maintaining lipid-lowering efficacy.

Overdose

There is no specific antidote for atorvastatin overdose. In case of suspected overdose, symptomatic and supportive measures should be instituted. Liver function and CK levels should be monitored. Rhabdomyolysis and renal failure have been reported in overdose situations; maintain hydration and consider urinary alkalization if rhabdomyolysis is suspected. Haemodialysis is not expected to significantly enhance elimination due to high protein binding.

Storage

Store below 30°C in the original packaging to protect from light and moisture. Keep out of reach and sight of children. Do not use after the expiration date printed on the packaging. Do not dispose of medication via wastewater or household waste; return unused tablets to a pharmacy for proper disposal.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalised dosage recommendations. Do not initiate, adjust, or discontinue Atorlip 20 without medical supervision. The manufacturer is not liable for any incorrect use, self-medication, or adverse outcomes resulting from the use of this information.

Reviews

Clinical studies and post-marketing surveillance demonstrate that Atorlip 20 effectively reduces LDL-C by 40–50% at this dose, with a favourable safety profile in most patients. Many clinicians note its reliability in achieving lipid targets, especially in moderate-risk patients. Long-term users often report improved lipid profiles and satisfaction with once-daily convenience, though some note mild gastrointestinal discomfort or muscle pain during initial therapy. Paediatric use under specialist supervision has shown promising results in familial hypercholesterolaemia management. Overall, it remains a well-tolerated and efficacious choice within its therapeutic class.